Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Malignant Melanoma of the Skin”

1,269 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,269 results

Not applicableStudy completedNCT04123678
What this trial is testing

DERM Health Economics Study

Who this might be right for
MelanomaNon-melanoma Skin Cancer
Skin Analytics Limited 700
Early research (Phase 1)Active Not RecruitingNCT05614102
What this trial is testing

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Bayer 284
Large-scale testing (Phase 3)UnknownNCT01088737
What this trial is testing

Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna

Who this might be right for
Lentigo Maligna
Medical University of Graz 60
Testing effectiveness (Phase 2)Study completedNCT01009177
What this trial is testing

Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)

Who this might be right for
Melanoma
Actelion 80
Testing effectiveness (Phase 2)WithdrawnNCT01851408
What this trial is testing

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Who this might be right for
MelanomaRecurrent MelanomaStage III Melanoma+1 more
National Cancer Institute (NCI)
Post-approval studies (Phase 4)UnknownNCT03313544
What this trial is testing

Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1

Who this might be right for
MelanomaNon-small CellLung Cancer
Assistance Publique Hopitaux De Marseille 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07339176
What this trial is testing

Intratumoral N17350 in Advanced Solid Tumors

Who this might be right for
Neoplasms, Solid TumorBreast Neoplasms, Triple-NegativeSquamous Cell Carcinoma of Skin+4 more
Onchilles Pharma Inc 275
Early research (Phase 1)Study completedNCT03817125
What this trial is testing

Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention

Who this might be right for
Metastatic Melanoma
Parker Institute for Cancer Immunotherapy 14
Large-scale testing (Phase 3)Study completedNCT00769704
What this trial is testing

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Who this might be right for
Melanoma
BioVex Limited 437
Not applicableLooking for participantsNCT07206017
What this trial is testing

Explorative Study on Addition of High-fiber Dried Chicory Root in Patients With an Intermediate to High-risk Cutaneous Melanoma.

Who this might be right for
Melanoma, Stage II
University Medical Center Groningen 20
Early research (Phase 1)Looking for participantsNCT05859074
What this trial is testing

MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Who this might be right for
Cutaneous Squamous Cell CarcinomaSCC - Squamous Cell CarcinomaBasal Cell Carcinoma+16 more
Memorial Sloan Kettering Cancer Center 56
Testing effectiveness (Phase 2)Active Not RecruitingNCT03999749
What this trial is testing

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Who this might be right for
Melanoma
NYU Langone Health 71
Testing effectiveness (Phase 2)Ended earlyNCT04157517
What this trial is testing

Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Who this might be right for
NeoplasmsMelanoma
Teva Branded Pharmaceutical Products R&D LLC 45
Testing effectiveness (Phase 2)Ended earlyNCT02062359
What this trial is testing

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma

Who this might be right for
Metastatic CancerMetastatic Melanoma
National Cancer Institute (NCI) 2
Testing effectiveness (Phase 2)Ended earlyNCT05219578
What this trial is testing

RTX-224 Monotherapy in Patients With Solid Tumors

Who this might be right for
Non Small Cell Lung CancerCutaneous MelanomaHead and Neck Squamous Cell Carcinoma+2 more
Rubius Therapeutics 7
Testing effectiveness (Phase 2)Study completedNCT00135408
What this trial is testing

MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide

Who this might be right for
Malignant Melanoma
Bristol-Myers Squibb 115
Not applicableStudy completedNCT00253708
What this trial is testing

Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer

Who this might be right for
Cancer
Beth Israel Deaconess Medical Center 39
Not applicableStudy completedNCT03139513
What this trial is testing

Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])

Who this might be right for
Melanoma
Hoffmann-La Roche 200
Testing effectiveness (Phase 2)Study completedNCT02643303
What this trial is testing

Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Who this might be right for
Head and Neck Squamous Cell CarcinomaBreast CancerSarcoma+8 more
Ludwig Institute for Cancer Research 58
Early research (Phase 1)UnknownNCT05103891
What this trial is testing

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

Who this might be right for
MelanomaBRAF V600 MutationUnresectable Melanoma+1 more
Pierre Fabre Medicament 14
Load More Results